CagriSema, developed by Novo Nordisk, is a fixed-dose combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analogue). This combination approach represents a different strategy in the metabolic research landscape.
The Combination Strategy
Rather than developing a single molecule that activates multiple receptors, CagriSema combines two distinct compounds:
Semaglutide: A well-characterised GLP-1 receptor agonist with established effects on insulin secretion, glucagon suppression, and gastric emptying.
Cagrilintide: A long-acting amylin analogue that activates amylin receptors. Amylin is a hormone co-secreted with insulin that has effects on gastric emptying, satiety, and glucagon secretion.
The rationale is that combining two complementary mechanisms may produce greater effects than either compound alone.
Research Findings
Clinical trials investigating CagriSema have generated several notable findings:
- Weight management: Phase 2 data showed greater weight reduction with the combination than with either component alone
- Glycaemic control: Improvements in HbA1c and fasting glucose have been observed
- Complementary mechanisms: The GLP-1 and amylin pathways appear to have additive effects on metabolic parameters
- Safety profile: The combination has been generally well-tolerated in clinical trials, with a safety profile consistent with the individual components
Phase 3 Progress
Novo Nordisk has been conducting multiple Phase 3 trials with CagriSema:
- REDEFINE trials: Investigating CagriSema for weight management in adults with obesity or overweight
- Cardiovascular outcomes: Long-term studies assessing cardiovascular safety and efficacy
- Diabetes studies: Examining effects in people with type 2 diabetes
The trials are large-scale and multinational, with Australian sites participating in several studies.
The Amylin Angle
The inclusion of cagrilintide (an amylin analogue) is what distinguishes CagriSema from other GLP-1 based compounds:
- Amylin physiology: Amylin is a peptide hormone that works alongside insulin to regulate glucose metabolism
- Complementary effects: Amylin and GLP-1 have overlapping but distinct effects on metabolic parameters
- Satiety signaling: Amylin has independent effects on satiety and gastric emptying that may complement GLP-1
This combination approach reflects a broader trend in metabolic research toward multi-pathway interventions.
Research Considerations
For those following CagriSema research:
- Combination pharmacology: Understanding how the two components work together is an active area of research
- Dosing optimization: The ratio of semaglutide to cagrilintide is being optimised in clinical trials
- Regulatory pathway: As a combination product, the regulatory pathway may differ from single-compound approvals
- Comparison with dual agonists: How CagriSema compares with dual GLP-1/GIP agonists like tirzepatide is a key research question
Community Interest
The research community has been following CagriSema with interest:
- Questions about how the combination compares with other approaches
- Interest in the amylin mechanism and its contribution to the overall effect
- Discussion of the regulatory timeline for Australian approval
- Comparison with retatrutide and other multi-pathway compounds
For more on the compounds involved, see our semaglutide and peptides overview. Join the discussion in our Telegram community.
Looking Ahead
CagriSema represents one of several multi-pathway approaches in the metabolic research pipeline. As Phase 3 data matures, researchers will gain a clearer understanding of how combination strategies compare with multi-receptor single molecules.
The compound’s progress also highlights the importance of amylin biology in metabolic research - an area that has received less attention than GLP-1 but may offer significant research opportunities.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.